Asian Pacific Journal of Cancer Prevention

  • 제15권7호
  • /
  • Pages.3191-3194
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Regulatory Mechanisms of Annexin-Induced Chemotherapy Resistance in Cisplatin Resistant Lung Adenocarcinoma

  • Wang, Chao (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Xiao, Qian (Department of Dermatology, Xijing Hospital, Fourth Military Medical University) ;
  • Li, Yu-Wen (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Zhao, Chao (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Jia, Na (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Li, Rui-Li (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Cao, Shan-Shan (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Cui, Jia (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Wang, Lu (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Wu, Yin (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University) ;
  • Wen, Ai-Dong (Department of Pharmacy, Xijing Hospital, Fourth Military Medical University)
  • 발행 : 2014.04.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Adenocarcinoma of lung has high incidence and a poor prognosis, woith chemotherapy as the main therapeutic tool, most commonly with cisplatin. However, chemotherapy resistance develops in the majority of patients during clinic treatment. Mechanisms of resistance are complex and still unclear. Although annexin play important roles in various tumor resistance mechanisms, their actions in cisplatin-resistant lung adenocarcinoma remain unclear. Preliminary studies by our group found that in cisplatin-resistant lung cancer A549 cells and lung adenocarcinoma tissues, both mRNA and protein expression of annexins A1, A2 and A3 is increased. Using a library of annexin A1, A2 and A3 targeting combined molecules already established by ourselves we found that specific targeting decreased cisplatin-resistance. Taken together, the underlined effects of annexins A1, A2 and A3 on drug resistance and suggest molecular mechanisms in cisplatin-resistant A549 cells both in vivo and in vitro. Furthermore, the study points to improved research on occurrence and development of lung adenocarcinoma, with provision of effective targets and programmes for lung adenocarcinoma therapy in the clinic.

키워드

참고문헌

  1. Cao Y, Li Y, Edelweiss M, et al (2008). Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol, 16, 530-4. https://doi.org/10.1097/PAI.0b013e31817432c3
  2. Chen CY, Shen JQ, Wang F, et al (2012). Prognostic Significance of Annexin A1 Expression in Pancreatic Ductal Adenocarcinoma. Asian Pac J Cancer Prev, 13, 4707-12. https://doi.org/10.7314/APJCP.2012.13.9.4707
  3. Emoto K, Sawada H, Yamada Y, et al (2001). Annexin II over-expression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res, 21, 1339-45.
  4. Esposito I, Penzel R, Chaib-Harrireche M, et al (2006). Tenascin C and annexin 2 expression in the process of pancreatic carcinogenesis. J Pathol, 208, 673-85. https://doi.org/10.1002/path.1935
  5. Fan Jiang, Jiang Ge-nin (2008). Advances in treatment of non-small cell lung cancer. Chinese J Clin, 2, 11-4.
  6. Fatimathas L, Moss SE (2010). Annexins as disease modifiers. Histol Histopathol, 25, 527-32.
  7. Gerke V, Creutz CE, Moss SE (2005). Annexins: linking $Ca^{2+}$ signalling to membrane dynamics. Nat Rev Mol Cell Biol, 6, 449-61. https://doi.org/10.1038/nrm1661
  8. Gillette JM, Chan DC, Nielsen-Preiss SM (2004). Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem, 92, 820-32. https://doi.org/10.1002/jcb.20117
  9. Huang Y, Jin Y, Yan CH, et al (2008). Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem, 309, 117-23. https://doi.org/10.1007/s11010-007-9649-5
  10. Langer CJ, Besse B, Gualberto A, et al (2010). The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol, 28, 5311-20. https://doi.org/10.1200/JCO.2010.28.8126
  11. Mussunoor S, Murray GI (2008). The role of annexins in tumour development and progression. J Pathol, 216, 131-40. https://doi.org/10.1002/path.2400
  12. Protzel C, Richter M, Poetsch M, et al (2011). The role of annexins I, II and IV in tumor development, progression and metastasis of human penile squamous cell carcinomas. World J Urol, 29, 393-8. https://doi.org/10.1007/s00345-010-0575-x
  13. Sharma MR, Koltowski L, Ownbey RT, et al (2006). Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol, 81, 146-56. https://doi.org/10.1016/j.yexmp.2006.03.003
  14. Stewart DJ, Chiritescu G, Dahrouge S, et al (2007). Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev, 33, 101-37. https://doi.org/10.1016/j.ctrv.2006.12.002
  15. Stewart DJ (2010). Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol, 75, 173-234. https://doi.org/10.1016/j.critrevonc.2009.11.006
  16. Sun DS, Hu LK, Cai Y, et al (2014). A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1233-9. https://doi.org/10.7314/APJCP.2014.15.3.1233
  17. Wang LP, Bi J, Yao C, et al (2010). Annexin A1 expression and its prognostic significance in human breast cancer. Neoplasma, 57, 253-9. https://doi.org/10.4149/neo_2010_03_253
  18. Wang H, Gui SY, Chen FH, et al (2013). New insights into 4-amino-2-tri-fluoromethyl-phenyl ester inhibition of cell growth and migration in the A549 lung adenocarcinoma cell line. Asian Pac J Cancer Prev, 14, 7265-70. https://doi.org/10.7314/APJCP.2013.14.12.7265
  19. Yan X, Yin J, Yao H, et al (2010). Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res, 70, 1616-24. https://doi.org/10.1158/0008-5472.CAN-09-3215
  20. Yee DS, Narula N, Ramzy I, et al (2007). Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med, 131, 902-8.
  21. Yu G, Wang J, Chen Y, et al (2008). Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis, 25, 695-702. https://doi.org/10.1007/s10585-008-9178-y
  22. Zhang MC, Hu CP (2006). Lung cancer molecular mechanisms of cisplatin resistance. Int J Respiration, 2, 152-5.
  23. Zhou YM, Liu J, Sun W (2014). MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev, 15, 1391-6. https://doi.org/10.7314/APJCP.2014.15.3.1391

피인용 문헌

  1. Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice vol.8, pp.4, 2014, https://doi.org/10.3892/ol.2014.2379
  2. Tumor Growth of Lung Cancer Cells vol.35, pp.10, 2016, https://doi.org/10.1089/dna.2016.3360
  3. Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis vol.13, pp.1, 2015, https://doi.org/10.1186/s12916-015-0392-6